NCT04661527 (STRIKESARS) is a Phase 2 clinical trial of Sarilumab in COVID-19 Drug Treatment, sponsored by Clinica Universidad de Navarra, Universidad de Navarra.

Who is sponsoring NCT04661527?

NCT04661527 is sponsored by Clinica Universidad de Navarra, Universidad de Navarra.

What drugs are being tested in NCT04661527?

Interventions in NCT04661527: Sarilumab.

What condition does NCT04661527 study?

NCT04661527 studies COVID-19 Drug Treatment.

Is NCT04661527 still recruiting?

NCT04661527 is currently status unknown. Last updated 16 December 2020.

Last reviewed 2020-12-16 · How we verify

NCT04661527: STRIKESARS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19

Status unknown Phase 2 Last updated 16 December 2020

What this trial tests

Phase 2 trial testing Sarilumab in COVID-19 Drug Treatment in 60 participants. Status unknown.

Timeline

22 April 2020

Primary endpoint
30 December 2020

30 December 2020

Quick facts

Lead sponsor	Clinica Universidad de Navarra, Universidad de Navarra
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	22 April 2020
Primary completion	30 December 2020
Estimated completion	30 December 2020
Sites	2 locations across Spain

Drugs / interventions tested

Sarilumab — full drug profile →

Conditions studied

COVID-19 Drug Treatment — all drugs for COVID-19 Drug Treatment →

Sponsor

Clinica Universidad de Navarra, Universidad de Navarra

Who can join

18 and older, any sex, with COVID-19 Drug Treatment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase II, one-arm, open label, multicentric study, to evaluate treatment of severe COVID-19 with sarilumab prior to entry into the intensive care unit (ICU).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy.
Zhang Q, Xiang R, Huo S, Zhou Y, et al · · 2021 · cited 219× · PMID 34117216 · DOI 10.1038/s41392-021-00653-w
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection.
Hwang YC, Lu RM, Su SC, Chiang PY, et al · · 2022 · cited 170× · PMID 34983527 · DOI 10.1186/s12929-021-00784-w
NETosis and Neutrophil Extracellular Traps in COVID-19: Immunothrombosis and Beyond.
Zhu Y, Chen X, Liu X. · · 2022 · cited 119× · PMID 35309344 · DOI 10.3389/fimmu.2022.838011
The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication.
Ning Q, Wu D, Wang X, Xi D, et al · · 2022 · cited 64× · PMID 35197452 · DOI 10.1038/s41392-022-00907-1
Inflammatory pathways in COVID-19: Mechanism and therapeutic interventions.
Jiang Y, Zhao T, Zhou X, Xiang Y, et al · · 2022 · cited 44× · PMID 35923762 · DOI 10.1002/mco2.154
Cytokine Storm Syndrome in SARS-CoV-2 Infections: A Functional Role of Mast Cells.
Hafezi B, Chan L, Knapp JP, Karimi N, et al · · 2021 · cited 41× · PMID 34359931 · DOI 10.3390/cells10071761
An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19).
Elahi R, Karami P, Heidary AH, Esmaeilzadeh A. · · 2022 · cited 33× · PMID 35074571 · DOI 10.1016/j.intimp.2022.108536
Peripheral T cell lymphopenia in COVID-19: potential mechanisms and impact.
Zhang S, Asquith B, Szydlo R, Tregoning JS, et al · · 2021 · cited 31× · PMID 35965490 · DOI 10.1093/immadv/ltab015

Verify or expand the search:

Other trials of Sarilumab

Trials testing the same drug.

NCT07286214 — Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica · Phase 4 · not yet recruiting
NCT07154290 — A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cel · Phase 2 · recruiting
NCT06787612 — Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer · Phase 2 · recruiting
NCT05535738 — Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation · Phase 2, PHASE3 · recruiting
NCT05125016 — A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for A · Phase 1, PHASE2 · recruiting

Other Clinica Universidad de Navarra, Universidad de Navarra trials

Trials by the same sponsor.

NCT07370571 — NO AXILLARY SURGERY IN EARLY BREAST CANCER (OXIGENATE) · not yet recruiting
NCT07165431 — Effect of a Postbiotic Supplementation in Overweight and Obese Subjects: A Randomized Controlled Trial (PARABIOTICS-2). · NA · recruiting
NCT07447440 — Role of Pro-Resolving Lipid Mediators in Obesity-Associated Diseases · recruiting
NCT07191210 — Co-Designed Comprehensive Transition Programme for First-Line Nurse Managers · NA · not yet recruiting
NCT07132060 — MRI-guided Dose Intensification Program Locally Advanced Pancreatic Cancer · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04661527 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Clinica Universidad de Navarra, Universidad de Navarra
Last refreshed: 16 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04661527.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing